SKYRIZI® (risankizumab) and RINVOQ® (upadacitinib) Data Highlight Long-Term Clinical and Endoscopic Outcomes Across Inflammatory Bowel Disease (IBD) at UEGW 2026
AbbVie is presenting 20 abstracts at UEG Week 2026 showcasing long-term and real-world data for its IBD franchise across SKYRIZI and RINVOQ. Headline results include upadacitinib maintaining clinical remission in 78.9%-86.6% of Crohn's disease patients at Week 144, and 70.2% of real-world Crohn's patients achieving clinical response within 12 weeks in the UPlift study. Late-breaking Phase 2a data on investigational dual-targeting therapy ABBV-466 showed endoscopic remission in moderate-to-severe Crohn's disease, supporting the pipeline beyond the marketed franchise.
Key figures
- Abstracts presented
- 20
- Upadacitinib realworld uplift response 12wk
- 70.2%
- Risankizumab uc week96 clinical remission range
- 54.0%-73.1%
- Upadacitinib cd week144 clinical remission 15mg
- 78.9%
- Upadacitinib cd week144 clinical remission 30mg
- 86.6%
- Risankizumab uc week96 endoscopic remission range
- 38.8%-53.5%
- Upadacitinib cd week144 endoscopic remission 15mg
- 47.1%
- Upadacitinib cd week144 endoscopic remission 30mg
- 64.2%
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.